Hirofumi Oyama, Shigeru Miwa, Tomoyuki Noda, Atsuhiro Sobajima, Akira Kito, Hideki Maki, Kenichi Hattori, Kentaro Wada
Index: Neurol. Med. Chir. (Tokyo) 52(10) , 769-73, (2012)
Full Text: HTML
A 51-year-old female with a history of rheumatoid arthritis rapidly developed anterior neck pain and paresis in the left upper and lower extremities and right lower extremity, sensory disturbance in the left upper and lower extremities, and bladder and rectal disorder. Adduction of the left eye and abduction of the right eye were also disturbed. Spinal magnetic resonance imaging demonstrated severe edema in the C1-T5 levels, which then deteriorated rapidly over 3 days, and lesions enhanced with gadolinium in the C1-C3 and C5-T3 levels. 2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography study demonstrated the inflammatory sites as segmental enhanced accumulation in the C1-C3, C5-C6, and T1 levels. The serum anti-aquaporin 4 antibody level was positive and she was diagnosed with neuromyelitis optica spectrum disorder. Marked improvement in the neurological conditions, concomitant with reduced spinal cord edema, was obtained by steroid pulse therapy.
| Structure | Name/CAS No. | Molecular Formula | Articles |
|---|---|---|---|
![]() |
Methylprednisolone succinate
CAS:2921-57-5 |
C26H34O8 |
|
Compatibility of intravenous fosaprepitant with intravenous ...
2013-09-01 [Cancer Chemother. Pharmacol. 72(3) , 509-13, (2013)] |
|
A misguided 'pill in the pocket' approach with flecainide le...
2012-01-01 [BMJ Case Rep. 2012 , doi:10.1136/bcr-2012-006868, (2012)] |
|
Shoe contact dermatitis: a case report of an acute severe re...
2012-09-01 [Foot (Edinb.) 22(3) , 141-5, (2012)] |
|
Ex vivomodels to evaluate the role of ocular melanin in tran...
2012-08-15 [Eur. J. Pharm. Sci. 46(5) , 475-83, (2012)] |
|
Successful treatment of anti-Caspr2 syndrome by interleukin ...
2013-08-01 [JAMA Neurol. 70(8) , 1056-9, (2013)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved
